Navigation Links
MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight

- First Patient Implanted in San Antonio, TX -

ORANGEBURG, N.Y., Nov. 28 /PRNewswire/ -- MetaCure Limited, today announced that it began patient enrollment in a national diabetes clinical trial of its TANTALUS(R) System, an investigational device being tested in patients with type 2 diabetes who are overweight. The study is being conducted in up to 30 sites in the United States.

The 300-patient trial will evaluate the TANTALUS, an implantable device that delivers electrical pulses to the stomach when a person eats. The primary objective of the randomized, double-blind controlled study is to evaluate the TANTALUS System in treating patients who have type 2 diabetes and are overweight. Impact on blood glucose levels, weight loss, blood pressure and other clinical and metabolic parameters will be studied. To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type 2 diabetes with a body mass index (BMI) between 28 and 45 kg/m2 and ages 18 to 70.

"Even with current medications and lifestyle changes, controlling blood glucose levels in type 2 diabetes patients who are overweight can be difficult," said Naji N. Abumrad, MD, MetaCure's Medical Director and John L. Sawyers Professor of Surgery and Chairman, Department of Surgery at Vanderbilt University Medical Center, Nashville, TN. "We are excited to have this trial underway as a potential alternative treatment for patients where we have been unsuccessful in managing their type 2 diabetes and weight."

Glandular Diseases Center of San Antonio, Texas, is the first trial site to enroll patients. "We are delighted to be participating in this trial and to be the initial center to implant the TANTALUS System in study patients," said Mark Kipnes, MD, of the Glandular Diseases Center.

"The TANTALUS System is currently CE marked and available to patients in Europe for the indication to treat type 2 diabetes with obesity. It has been clinically evaluated in more than 100 patients world wide," explained Dr. Irit Yaniv, MetaCure's Chief Operating Officer. "We look forward to potentially being able to make it accessible in the future to U.S. patients as well."

For more information about the study, please go to

More About the TANTALUS System

The TANTALUS System includes a pulse generator and leads that are implanted through a minimally invasive laparoscopic procedure that can be performed in an outpatient setting. The leads are implanted in the gastric muscle and the device is implanted in a subcutaneous pocket.

The system is based on new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meal times.

About MetaCure

MetaCure Limited was founded in 2003 and is developing minimally invasive solutions for today's most pressing global epidemic, type 2 diabetes. Its flagship product, the TANTALUS System, has already been granted the CE mark in Europe. The company's corporate U.S. offices are based in Orangeburg, New York, and Mt. Laurel, New Jersey. For more information, visit

Media Contact For MetaCure:

Erich Sandoval of Lazar Partners

Tel. 212-867-1773


SOURCE MetaCure Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
6. Easter Seals Launches Program for Veterans Returning from Iraq and Afghanistan with Traumatic Brain Injuries
7. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
8. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
9. Mannatech Launches Phase One of New Sales and Training Tools
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. Actavis Launches Carvedilol Tablets in the U.S.
Post Your Comments:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: